Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $476.95, moving +1.45% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.78% ...

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

Valued at a market cap of $117.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that ...

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can ...

VRTX is getting a Phase 3-ready development drug in povetacicept, VRTX getting a “pipeline in a product” (meaning there are other potential indications the drug could be applied to), and; ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the May 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...